Selected research
Industry Research
Generic Injectable Drugs Industry Research Report 2026
Market perspective
The global Generic Injectable Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Generic Injectable Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Generic Injectable Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Generic Injectable Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Generic Injectable Drugs include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Generic Injectable Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Generic Injectable Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Generic Injectable Drugs Market by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectable Drugs Segment by Type
Small Molecule
Large Molecule
Generic Injectable Drugs Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectable Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectable Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectable Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectable Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Injectable Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Large Molecule
Applications
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
Companies covered
- Hospira (Pfizer Inc.)
- Fresenius Kabi
- Sandoz (Novartis)
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd
- Grifols
- Nichi-Iko Group (Sagent)
- Teva Pharmaceutical
- Auromedics
- Sanofi
- Gland Pharma
- Endo International PLC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Generic Injectable Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecule
- 2.2.3 Large Molecule
- 2.3 Generic Injectable Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Anesthesia
- 2.3.4 Anti-Infectives
- 2.3.5 Parenteral Nutrition
- 2.3.6 Cardiovascular Diseases
- 2.4 Assumptions and Limitations
3 Generic Injectable Drugs Breakdown Data by Type
- 3.1 Global Generic Injectable Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Generic Injectable Drugs Forecasted Market Size by Type (2027-2032)
4 Generic Injectable Drugs Breakdown Data by Application
- 4.1 Global Generic Injectable Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Generic Injectable Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Generic Injectable Drugs Market Perspective (2021-2032)
- 5.2 Global Generic Injectable Drugs Growth Trends by Region
- 5.2.1 Global Generic Injectable Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Generic Injectable Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Generic Injectable Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Generic Injectable Drugs Market Dynamics
- 5.3.1 Generic Injectable Drugs Industry Trends
- 5.3.2 Generic Injectable Drugs Market Drivers
- 5.3.3 Generic Injectable Drugs Market Challenges
- 5.3.4 Generic Injectable Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Generic Injectable Drugs Players by Revenue
- 6.1.1 Global Top Generic Injectable Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Generic Injectable Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Generic Injectable Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Generic Injectable Drugs Head Office and Area Served
- 6.4 Global Generic Injectable Drugs Players, Product Type & Application
- 6.5 Global Generic Injectable Drugs Manufacturers Established Date
- 6.6 Global Generic Injectable Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Generic Injectable Drugs Market Size (2021-2032)
- 7.2 North America Generic Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Generic Injectable Drugs Market Size by Country (2021-2026)
- 7.4 North America Generic Injectable Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Generic Injectable Drugs Market Size (2021-2032)
- 8.2 Europe Generic Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Generic Injectable Drugs Market Size by Country (2021-2026)
- 8.4 Europe Generic Injectable Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Generic Injectable Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Generic Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Generic Injectable Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Generic Injectable Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Generic Injectable Drugs Market Size (2021-2032)
- 10.2 South America Generic Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Generic Injectable Drugs Market Size by Country (2021-2026)
- 10.4 South America Generic Injectable Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Generic Injectable Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Generic Injectable Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Generic Injectable Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Generic Injectable Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Hospira (Pfizer Inc.)
- 12.1.1 Hospira (Pfizer Inc.) Company Information
- 12.1.2 Hospira (Pfizer Inc.) Business Overview
- 12.1.3 Hospira (Pfizer Inc.) Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.1.4 Hospira (Pfizer Inc.) Generic Injectable Drugs Product Portfolio
- 12.1.5 Hospira (Pfizer Inc.) Recent Developments
- 12.2 Fresenius Kabi
- 12.2.1 Fresenius Kabi Company Information
- 12.2.2 Fresenius Kabi Business Overview
- 12.2.3 Fresenius Kabi Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.2.4 Fresenius Kabi Generic Injectable Drugs Product Portfolio
- 12.2.5 Fresenius Kabi Recent Developments
- 12.3 Sandoz (Novartis)
- 12.3.1 Sandoz (Novartis) Company Information
- 12.3.2 Sandoz (Novartis) Business Overview
- 12.3.3 Sandoz (Novartis) Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.3.4 Sandoz (Novartis) Generic Injectable Drugs Product Portfolio
- 12.3.5 Sandoz (Novartis) Recent Developments
- 12.4 Hikma Pharmaceuticals PLC
- 12.4.1 Hikma Pharmaceuticals PLC Company Information
- 12.4.2 Hikma Pharmaceuticals PLC Business Overview
- 12.4.3 Hikma Pharmaceuticals PLC Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.4.4 Hikma Pharmaceuticals PLC Generic Injectable Drugs Product Portfolio
- 12.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 12.5 Dr. Reddy’s Laboratories Ltd
- 12.5.1 Dr. Reddy’s Laboratories Ltd Company Information
- 12.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
- 12.5.3 Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Product Portfolio
- 12.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
- 12.6 Grifols
- 12.6.1 Grifols Company Information
- 12.6.2 Grifols Business Overview
- 12.6.3 Grifols Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.6.4 Grifols Generic Injectable Drugs Product Portfolio
- 12.6.5 Grifols Recent Developments
- 12.7 Nichi-Iko Group (Sagent)
- 12.7.1 Nichi-Iko Group (Sagent) Company Information
- 12.7.2 Nichi-Iko Group (Sagent) Business Overview
- 12.7.3 Nichi-Iko Group (Sagent) Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.7.4 Nichi-Iko Group (Sagent) Generic Injectable Drugs Product Portfolio
- 12.7.5 Nichi-Iko Group (Sagent) Recent Developments
- 12.8 Teva Pharmaceutical
- 12.8.1 Teva Pharmaceutical Company Information
- 12.8.2 Teva Pharmaceutical Business Overview
- 12.8.3 Teva Pharmaceutical Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.8.4 Teva Pharmaceutical Generic Injectable Drugs Product Portfolio
- 12.8.5 Teva Pharmaceutical Recent Developments
- 12.9 Auromedics
- 12.9.1 Auromedics Company Information
- 12.9.2 Auromedics Business Overview
- 12.9.3 Auromedics Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.9.4 Auromedics Generic Injectable Drugs Product Portfolio
- 12.9.5 Auromedics Recent Developments
- 12.10 Sanofi
- 12.10.1 Sanofi Company Information
- 12.10.2 Sanofi Business Overview
- 12.10.3 Sanofi Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.10.4 Sanofi Generic Injectable Drugs Product Portfolio
- 12.10.5 Sanofi Recent Developments
- 12.11 Gland Pharma
- 12.11.1 Gland Pharma Company Information
- 12.11.2 Gland Pharma Business Overview
- 12.11.3 Gland Pharma Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.11.4 Gland Pharma Generic Injectable Drugs Product Portfolio
- 12.11.5 Gland Pharma Recent Developments
- 12.12 Endo International PLC
- 12.12.1 Endo International PLC Company Information
- 12.12.2 Endo International PLC Business Overview
- 12.12.3 Endo International PLC Revenue in Generic Injectable Drugs Business (2021-2026)
- 12.12.4 Endo International PLC Generic Injectable Drugs Product Portfolio
- 12.12.5 Endo International PLC Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst